Moreover, elafin administration suppressed the inflammatory response by reducing the levels of IBD-related pro-inflammatory cytokines including IL-6, IL-8, IL-17, TNF-α, as well as down-regulating the NF-κB pathway [24,25,26]. Here, NFKB1 is linked to irritable bowel syndrome.